Clinical study on platinum-based chemotherapy In elderly patients with advanced non-small cell lung cancer
- VernacularTitle:以铂类为基础的两药联合方案治疗老年晚期非小细胞肺癌临床研究
- Author:
Bo LU
;
Xiaotong ZHANG
;
Longyun LI
;
Li ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Antineoplastic combined chemotherapy protocols;
Platinum compounds
- From:
Chinese Journal of Geriatrics
2008;27(11):801-804
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of platinum-based chemotherapy in elderly patients with advanced non-small cell lung cancer(NSCLC). Methods Clinical data of forty-one elderly patients (≥70 years) with advanced NSCLC who were treated by platinum-based chemotherapy were analyzed retrospectively. Results Among the 41 patients, 18 (43.9%) patientswere treated with vinorelbine, 9 (22.0%) patients with gemcitabine, 7 (17.1%) patients with paclitaxel and docetaxel respectively. The overall response rate was 19.5%. The median time to progression (MTTP) was 5.8 months, and 1-year survival rate was 65.8% with a median survival time (MST) of 14.2 months. No significant statistical differences were found among the four regimens. The major side effect was bone marrow suppression. Three patients withdrew chemotherapy after one cycle due to grade Ⅲ-Ⅳ myelosuppression. There was no death associated with chemotherapy. Conclusions The platinum-based combined chemotherapy is effective and well-tolerated in elderly patients with advanced NSCLC.
